Tables S1, S2, S4, S8, S9 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Authors:
  • JRJulia Reinhardt
    Julia Reinhardt
  • JLJennifer Landsberg
    Jennifer Landsberg
  • JSJonathan L. Schmid-Burgk
    Jonathan L. Schmid-Burgk
  • BRBartomeu Bibiloni Ramis
    Bartomeu Bibiloni Ramis
  • TBTobias Bald
    Tobias Bald
  • NGNicole Glodde
    Nicole Glodde
  • DLDorys Lopez-Ramos
    Dorys Lopez-Ramos
  • AYArabella Young
    Arabella Young
  • SNShin Foong Ngiow
    Shin Foong Ngiow
  • DNDaniel Nettersheim
    Daniel Nettersheim
  • HSHubert Schorle
    Hubert Schorle
  • TQThomas Quast
    Thomas Quast

Abstract
Supplemental Table S1. DNA oligos used in this study Supplemental Table S2. Characteristics of patients with primary melanomas and cutaneous melanoma metastasis (Bonn cohorts). Supplemental Table S4. List of transcription factors binding in NT5E based on ENCODE ChIP-seq data. Supplemental Table S8. Changes of CD73 IHC score in melanoma patients from the UCLA cohort under pembrolizumab treatment (anti-PD-1). Supplemental Table S9. Characteristics and changes of CD73 expressions of melanomas from patients of the Sydney cohort treated with nivolumab or pembrolizumab (anti PD-1).